ImmunityBio (NASDAQ:IBRX) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.
Profitability
This table compares ImmunityBio and Kinnate Biopharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
ImmunityBio | N/A | N/A | N/A |
Kinnate Biopharma | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for ImmunityBio and Kinnate Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
ImmunityBio | 0 | 0 | 1 | 0 | 3.00 |
Kinnate Biopharma | 0 | 0 | 4 | 0 | 3.00 |
ImmunityBio presently has a consensus price target of $25.00, suggesting a potential upside of 48.19%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 64.82%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe Kinnate Biopharma is more favorable than ImmunityBio.
Earnings & Valuation
This table compares ImmunityBio and Kinnate Biopharma's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
ImmunityBio | N/A | N/A | N/A | N/A | N/A |
Kinnate Biopharma | N/A | N/A | N/A | N/A | N/A |
Summary
Kinnate Biopharma beats ImmunityBio on 2 of the 2 factors compared between the two stocks.